Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We are looking for healthy adults to take part in the initial trial of a potential new vaccine against a virus considered to be a crucial missing element in the childhood vaccination programme. **Please note, this study has recruited a sufficient number of participants**

Respiratory syncytial virus (RSV) kills around 200,000 people worldwide each year. Both the elderly and infants are especially vulnerable to developing severe disease with RSV. Two-thirds of babies are infected with RSV before their first birthday and in winter the virus causes annual epidemics resulting in up to 15 out of every 100 admissions to children’s wards. In the world’s poorer areas, RSV is second only to malaria as a killer of children aged between 1 and 12 months.

In early August, the Oxford Vaccine Group, part of the University’s Department of Paediatrics, announced that the first trial of a different potential RSV vaccine had been successful. Building on the results of this study, the Group is ready to begin trials of a new version of this potential RSV vaccine.

Dr Matthew Snape from the Oxford Vaccine Group, is Chief Investigator leading the study of the new vaccine candidate. He explained: ‘Vaccine development is a long process and it is important to ensure that the best potential vaccine is taken forward for testing in larger numbers. This is why we are testing a new version of the vaccine.

‘As a paediatrician I am all too aware of the enormous burden of disease that RSV brings every winter. It is tremendously exciting to be part of an RSV vaccine programme, and the current study is an important next step towards developing a vaccine to be used in infants.’

The potential vaccine is known as a ‘viral vectored vaccine.’ That means that it uses a virus (the vector), in this case an adenovirus called ChAd155, to carry proteins from RSV that trigger the immune system to respond against it. Neither the RSV proteins nor the carrier virus can replicate and cause infection. Two injections are used: the first is expected to stimulate the immune system to prompt a response; the second is expected to strengthen the immune response triggered by the first. The complete modified product is called ChAd155-RSV.

To assess this new vaccine, the team is planning to carry out what is called a phase 1 clinical trial. In this phase, a small number of healthy adult volunteers receive the vaccine to assess whether it is safe and tolerated and it prompts the immune system to respond. If successful, it is planned that further trials will assess the effectiveness and safety of ChAd155-RSV in children – the main group who would benefit from a licensed RSV vaccine.

They are now looking for 72 volunteers from in and around Oxford, aged between 18 and 45.

To find out more visit www.ovg.ox.ac.uk/trials/RSV or call 01865 857420.

 

Funding:

The work of the Oxford Vaccine Group is supported by the NIHR Oxford Biomedical Research Centre, and the conduct of the RSV study is being sponsored by global healthcare company GSK, who have manufactured the vaccine.

Similar stories

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

COVID-19 Research Vaccinology

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK

COVID-19 Research Vaccinology

A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants.

Oxford leads first trial investigating dosing with alternating vaccines

COVID-19 Clinical Trials Vaccinology

The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.

Oxford University vaccine developer joins day of vaccinations at the Kassam Stadium

COVID-19 Vaccinology

Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

COVID-19 Vaccinology

University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

Oxford University breakthrough on global COVID-19 vaccine

COVID-19 Vaccinology

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.